Redirection of human autoreactive T-cells upon interaction with dendritic cells modulated by TX527, an analog of 1,25 dihydroxyvitamin D3

Diabetes

Volumn 51, Issue 7, 2002, Pages 2119-2125

  Van Halteren, Astrid G S ^a   Van Etten, Evelyne ^b   De Jong, Esther C ^c   Bouillon, Roger ^b   Roep, Bart O ^a   Mathieu, Chantal ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

19 NOR 14,20 BISEPI 23 YNE CALCITRIOL; CALCITRIOL; CALCITRIOL DERIVATIVE; CD1 ANTIGEN; CD14 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; HORMONAL REGULATION; HUMAN; HUMAN CELL; IMMUNOMODULATION; LYMPHOCYTE PROLIFERATION; NORMAL HUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0036306094     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.51.7.2119     Document Type: Article

References (38)

1. The NOD mouse model of type 1 diabetes: As good as it gets?
2. Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients
3. 1,25-Dihydroxyvitamin D3 prevents insulitis in NOD mice
4. Prevention of autoimmune diabetes in NOD mice by 1,25 dihydroxyvitamin D3
5. Intake of vitamin D and risk of type 1 diabetes: A birth control study
6. Immunomodulatory actions of 1,25-dihydroxyvitamin D3
7. Recent developments in the use of vitamin D analogs
8. 1α,25-dihydroxyvitamin D3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells
9. Inhibition of IL-12 production by 1,25- dihydroxyvitamin D3. Involvement of NF-κB downregulation in transcriptional repression of the p 40 gene
10. 1α,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation
11. Dendritic cell modulation by 1α,25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo
12. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells
13. Structure-function relationships in the vitamin D endocrine system
14. Prevention of type 1 diabetes in nonobese diabetic mice by late intervention with nonhypercalcemic analogs of 1,25-dihydroxyvitamin D3 in combination with a short induction course of cyclosporin A
15. Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice by a combination of a vitamin D3 analog and cyclosporine
16. 1α,25-dihydroxyvitamin D3 induces an autoantigen-specific T-helper 1/T-helper 2 immune shift in NOD mice immunized with GAD65 (p524-543)
17. Regulatory T cells induced by 1α,25-dihydroxyvitamin D(3) and mycophenolate mofetil treatment mediate transplantation tolerance
18. GAD65-reactive T cells in a non-diabetic stiff-man syndrome patient
19. Two novel 14-Epi-analogues of 1,25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo
20. Interaction of two novel 14-epivitamin D3 analogs with vitamin D3 receptor-retinoid X receptor heterodimers on vitamin D 3 responsive elements
21. Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: Decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells
22. Activation of human dendritic cells through CD40 crosslinking
23. Cytomegalovirus in autoimmunity: T cell crossreactivity to viral antigen and autoantigen glutamic acid decarboxylase
24. Analogs of 1,25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosuppressants
25. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction
26. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha
27. T-cell priming by type-1 and type-2 polarized dendritic cells: The concept of a third signal
28. Corticosteroids inhibit the production of inflammatory mediators in immature monocyte-derived DC and induce the development of tolerogenic DC3
29. Glucocorticoids inhibit bioactive IL-12p7O production by in vitro-generated human dendritic cells without affecting their T cell stimulatory potential
30. Inhibition of human dendritic cell functions by methylprednisolone
31. Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10
32. Molecular cloning and characterization of a human metalloprotease disintegrin: A novel marker for dendritic cell differentiation
33. Dendritic cells as the terminal stage of monocyte differentiation
34. Monocyte-derived dendritic cells: A potential target for therapy in multiple sclerosis (MS)
35. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages
36. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
37. Regulatory CD4 T cells: Expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency
38. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes